Nina Niu Sanford, Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital, shared an article by Mustafa M.Basree, et al. on X:
“Ph I trial of pre-op SBRT for resectable pancreas ca: R0 resection rate 100%.
Vs NORPACT1 neoadjuvant chemo arm alone R0 56%.
Await clinical outcomes, but what other disease site accepts R1 resection in ~1/2 of patients?
Pre-op RT for select resectable PDAC will be way to go.”
Neoadjuvant SBRT plus Elective Nodal Irradiation with Concurrent Capecitabine for Patients with Resectable Pancreatic Cancer: Survival Analysis of a Prospective Phase 1 Trial.
Authors: Mustafa M. Basree, et al.
